aTyr Pharma Inc (LIFE)
1.62
+0.04
(+2.27%)
USD |
NASDAQ |
Apr 18, 16:00
1.62
0.00 (0.00%)
After-Hours: 19:40
aTyr Pharma Research and Development Expense (Quarterly): 12.76M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.76M |
| September 30, 2023 | 10.32M |
| June 30, 2023 | 9.84M |
| March 31, 2023 | 9.379M |
| December 31, 2022 | 14.91M |
| September 30, 2022 | 9.867M |
| June 30, 2022 | 9.135M |
| March 31, 2022 | 8.896M |
| December 31, 2021 | 5.955M |
| September 30, 2021 | 5.138M |
| June 30, 2021 | 7.655M |
| March 31, 2021 | 4.516M |
| December 31, 2020 | 4.698M |
| September 30, 2020 | 4.616M |
| June 30, 2020 | 4.361M |
| March 31, 2020 | 3.616M |
| December 31, 2019 | 3.59M |
| September 30, 2019 | 3.799M |
| June 30, 2019 | 3.314M |
| March 31, 2019 | 3.345M |
| Date | Value |
|---|---|
| December 31, 2018 | 3.549M |
| September 30, 2018 | 4.202M |
| June 30, 2018 | 6.484M |
| March 31, 2018 | 6.15M |
| December 31, 2017 | 5.31M |
| September 30, 2017 | 7.133M |
| June 30, 2017 | 8.42M |
| March 31, 2017 | 9.204M |
| December 31, 2016 | 9.144M |
| September 30, 2016 | 10.40M |
| June 30, 2016 | 11.31M |
| March 31, 2016 | 12.00M |
| December 31, 2015 | 12.67M |
| September 30, 2015 | 7.739M |
| June 30, 2015 | 7.502M |
| March 31, 2015 | 6.593M |
| December 31, 2014 | 4.341M |
| September 30, 2014 | 4.41M |
| June 30, 2014 | 3.638M |
| March 31, 2014 | 4.388M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.314M
Minimum
Jun 2019
14.91M
Maximum
Dec 2022
7.177M
Average
5.955M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Vaxart Inc | 14.70M |
| Allogene Therapeutics Inc | 54.66M |
| AIM ImmunoTech Inc | 3.20M |
| Protalix BioTherapeutics Inc | 3.102M |
| Armata Pharmaceuticals Inc | 7.928M |